Mesenchymal stem cells: Immunomodulatory properties and clinical application;Mezenhimske matičně stanice: Imunomodulatorne značajke i klinická primjena

Lijecnicki Vjesnik

Volumn 134, Issue 1-2, 2012, Pages 42-49

  Golemović, Mirna ^a,b   Marijana, Škifić ^a   Branka, Golubić Ćepulić ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b NONE   (Croatia)

Author keywords

Immunomodulation; Mesenchimal stem cell transplantation; Mesenchymal stem cells Immunology; Multipotent stem cells Immunology

Indexed keywords

HUMAN; IMMUNOLOGY; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; REVIEW;

HUMANS; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS;

EID: 84859480823     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. 1. Bonnet D. Biology of human bone marrow stem cells. Clin Exp Med 2003;3(3): 140-9. (Pubitemid 37491543)
2. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP Heterotropic transplants of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968;6:230-47.
3. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976; 4(5):267-74.
4. Ashton BA, Allen TD, Howlett CR i sur. Formation of bone and cartilage by marrow stromal cells in diffusion chambers in vivo. Clin Orthop Relat Res 1980;150:294-307.
5. Castro-Malaspina H, Gay RE, Resnik G i sur. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 1980;56(2):289-301.
6. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991;9:641-50.
7. Aerts F, Wagemaker G. Mesenchymal stem cell engineering and transplantation. U: Nolta JA, ur. Genetic engineering of mesenchymal stem cells. Dordrecht: Springer; 2006, str. 1-44.
8. Bieback K, Eichler H. Human Mesenchymal Stromal Cells. U: Areman EM, Loper K, ur. Cellular Therapy: Principles, Methods and Regulations. Bethesda: AABB 2009;448-66.
9. Lu LL, Liu YJ, Yang SG i sur. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematology 2006;91:1017-26.
10. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110(10):3499-506. (Pubitemid 350159613)
11. Friedenstein AJ. Marrow stromal fibroblasts. Calcif Tissue lnt 1995; 56(Suppl 1):S17.
12. Colter DC, Class R, DiGirolamo CM, Prockop DJ. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci USA 2000;97(7):3213-8. (Pubitemid 30183281)
13. Haynesworth SE, Baber MA, Captan AI. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 1992;13(1):69-80.
14. Gronthos S, Simmons PJ, Graves SE, Robey PG. Integrin-mediated interactions between human bone marrow stromal precursor cells and the extracellular matrix. Bone 2001;28(2):174-81. (Pubitemid 32140973)
15. Zuk PA, Zhu M, Ashjian P i sur. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002;13(12):4279-95.
16. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: Mesenchymal stem cells; their phenotype, differentiation capacity, immunological features and potential for homing. Stem Cells 2007;25(11): 2739-49. (Pubitemid 350127858)
17. Owen M, Friedenstein AJ. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp 1988;(136):42-60.
18. Pittenger MF, Mackay AM, Beck SC i sur. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284(5411): 143-7.
19. Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger MF. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng 1998;4(4):415-28. (Pubitemid 28553528)
20. Wakitani S, Saito T, Caplan AI. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve 1995; 18(12): 1417-26.
21. ZhangYN, Lie PC, Wei X. Differentiation of mesenchymal stromal cells derived from umbilical cord Wharton's jelly into hepatocyte-like cells. Cytother 2009; 11 (5):548-58.
22. Mareschi K, Rustichelli D, Comunanza V i sur. Multipotent mesenchymal stem cells from amniotic fluid originate neural precursors with functional voltage-gated sodium channels. Cytother 2009; 11(5):534-47.
23. Rubio D, Garcia-Castro J, Martin MC i sur. Spontaneous human adult stem cell transformation. Cancer Res 2005;65(8):3035-9.
24. Barlow S, Brooke G, Chatterjee K i sur. Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev 2008;17(6):1095-107.
25. Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: paradoxes of passaging. Exp Hematol 2004;32(5):414-25. (Pubitemid 38624325)
26. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringdén O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57(1):11-20. (Pubitemid 38019084)
27. Di Nicola M, Carlo-Stella C, Magni M i sur. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99(10):3838-43.
28. Troeger A, Meisel R, Moritz T, Dilloo. Immunotherapy in allogeneic hematopoietic stem cell transplantation - not just a case for effector cells. Bone Marrow Transplant 2005;35:59-64.
29. Ramasamy R, Ringden O, Sundberg B, LeBlanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplant 2003;76: 1208-13. (Pubitemid 37339646)
30. Lazarus HM, Koc ON, Devine SM i sur. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11(5):389-98.
31. Ringdén O, Labopin M, Gorin NC i sur. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004;22 (3):416-23. (Pubitemid 41079769)
32. Avanzini MA, Bernardo ME, Cometa AM i sur. Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematology 2009;94(10):1649-60.
33. Schugar RC, Chirieleison SM, Wescoe KE i sur. High harvest yield, high expansion, and phenotype stability of CD 146 mesenchymal stromal cells from whole primitive human umbilical cord tissue. J Biomed Biotechnol 2009;2009: article ID 789526.
34. Bacigalupo A. Mesenchymal stem cells and haematopoietic stem cell transplantation. Best Pract Res Clin Haematol 2004;17:387-99. (Pubitemid 39462571)
35. Dominici M, LeBlanc K, Mueller I i sur. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytother 2006;8(4):315-7.
36. Koç ON, Peters C, Aubourg P i sur. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp Hematol 1999;27(11): 1675-81.
37. Bartmann C, Rohde E, Schallmoser K i sur. Two steps to functional mesenchymal stromal cells for clinical application. Transfusion 2007; 47(8): 1426-35.
38. Le Blanc K, Frassoni F, Ball L i sur. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371(9624): 1579-86.
39. Von Bonin M, Stozel F, Goedecke A i sur. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009;43(3):245-51.
40. Zappia E, Casazza S, Pedemonte E i sur. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106(5):1755-61.
41. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002;62(13):3603-8. (Pubitemid 34728832)
42. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cell Tissues Organs 2001;169:12-20. (Pubitemid 32437040)
43. Zonta S, De Martino M, Bedino G i sur. Which Is the Most Suitable and Effective Route of Administration for Mesenchymal Stem Cell-Based Immunomodulation Therapy in Experimental Kidney transplantation: Endovenous or Arterial? Transplant Proc 2010;42(4): 1336-40.
44. Lataillade JJ, Doucet C, Bey E i sur. New approach to radiation burn treatment by dosimetry-guided surgery combined with autologous mesenchymal stem cell therapy. Regen med 2007;2(5):785-94.
45. Lazarus HM, Haynesworth SE, gerson SL, Rosenthal NS, Caplan Al. Ex vivo expansion and subsequent infusion of human bone marrowderived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995;16:557-64.
46. Horowitz EM, Gordon PL, Koo WW i sur. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci 2002;99:8932-7.
47. Galotto M, Berisso G, Delfino L i sur. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol 1999;27:1460-66.
48. Koç ON. Clinical trials of human mesenchymal stem cells to support hematopoietic stem cell transplantation. U: Nolta JA. (ur.); Genetic Engineering of Mesenchymal Stem Cells. Nizozemska; Springer;2006: 151-62.
49. Lazarus HM, Koc ON, Devine SM i sur. Cotransplantation of HLAidentical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11(5):389-98.
50. Jethva R, Otsuru S, Dominici M, Horwitz EM. Cell therapy for disorders of bone. Cytother 2009:11(1);3-17.
51. Horwitz EM, Gordon PL. Bone marrow mesenchymal stem cell transplantation for children with severe osteogenesis imperfecta. U: Nolta JA, ur. Genetic engineering of mesenchymal stem cells. Dordrecht: Springer; 2006, str. 135-50.
52. Pereira RF, O'Hara MD, Laptev AV i sur. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with phenotype of osteogenesis imperfecta. Proc Natl Acad Sci 1998;95:1142-7.
53. Horowitz EM, Prokop DJ, Fitzpatrick LA i sur. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Mat Med 1999;5:309-13.
54. Horwitz EM, Prather WR. Cytokines as the major mechanism of mesenchymal stem cell clinical activity: Expanding the spectrum of cell therapy. Isr Med Assoc J 2009; 11 (4):209-l 1.
55. Vija L, Farge D, Gautier JF i sur. Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes. Diabetes Metab 2009;35(2): 85-93.
56. Koblas T, Mitchell Harman S, Saudek F. The application of umbilical cord blood cells in the treatment of diabetes mellitus. Rev Diabetic Stud 2005;2:228-34.
57. Haller MJ, Viener HL, Wasserfall C, Brusko T, Atkinson MA. Schatz DA. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol 2008;36(6):710-15.
58. Yuan H, Li J, Xin N, Zhao Z, Qin G. Expression of Pdx 1 mediates differentiation from mesenchymal stem cells into insulin-producing cells. Mol Biol Rep 2010 Mar21 (Epub ahead of print).
59. Bey E, Duhamel P, Lataillade JJ, de Revel T, Carsin H, Gourmelon P. Treatment of radiation bums with surgery and cell therapy. A report of two cases. Bull Acad Natl Med 2007; 191 (6):971-8.
60. Lataillade JJ, Doucet C, Bey E i sur. New approach to radiation burn treatment by dosimetry-guided surgery combined with autologous mesenchymal stem cell therapy. Regen med 2007;2(5):785-94.
61. Ma N, Ladilov Y, Kaminski A i sur. Umbilical cord blood cell transplantation for myocardial regeneration. Transplant Proc 2006;38:771-3.
62. Tan G, Shim W, Gu Y i sur. Differential effect of myocardial matrix and integrins on cardiac differentiation of human mesenchymal stem cells. Differentiation 2010 Mar 20. (Epub ahead of print)
63. Li Q, Turdi S, Thomas DP, Zhou T, Ren J. Intra-myocardial delivery of mesenchymal stem cells ameliorates left ventricular and cardiomyocyte contractile dysfunction following myocardial infarction. Toxicol Lett 2010 Mar 18. (Epub ahead of print)
64. Noort WA, Feye D, Van Den Akker F i sur. Mesenchymal stromal cells to treat cardiovascular disease: strategies to improve survival and therapeutic results. Panminerva Med 2010 Mar;52(1):27-40.